Antibiotic resistance in low- and middle-income countries: current practices and its global implications

Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(12):1281-1286. doi: 10.1080/14787210.2023.2268835. Epub 2023 Nov 24.

Abstract

Introduction: Antibiotic consumption rates are high in both high and low-income countries, but addressing antibiotic practices in low- and middle-income countries (LMICs) is crucial to combatting antibiotic resistance (AR).

Area covered: This editorial examines the current landscape of antibiotic practices in LMICs, investigate the factors driving such trends including lack of resource equity and shared global responsibility, and explore (AR) global implications, with particular emphasis placed on swift measures to combat its spread.

Expert opinion: LMICs face three key obstacles that exacerbate AR: inadequate WASH services, climate factors, and misuse of antibiotics. A lack of sanitation and clean water promotes infections, while poor hygiene exacerbates resistant pathogen spread. Global strategies should go beyond simply educating LMICs about antibiotic misuse; they must also understand its repercussions, such as prolonged illnesses and drug-resistant bacteria like MRSA. Addressing this challenge requires multifaceted strategies, including improving WASH services, acknowledging climate impacts, and tightening regulations. Prioritizing WASH requires significant funding, community participation, technology solutions, and partnerships with NGOs. Utilizing social media influencers can boost AR awareness. Antibiotic regulation reforms, manufacturing quality, and seeking antibiotic alternatives are vital. Antimicrobial Stewardship Programs and AI's potential in managing resistant infections are notable.

Keywords: Antibiotic resistance (AR); Health equity; WASH services; antimicrobial stewardship programs; low and middle-income countries (LMICs).

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Antimicrobial Stewardship*
  • Bacteria
  • Developing Countries*
  • Drug Resistance, Microbial
  • Humans

Substances

  • Anti-Bacterial Agents